An innovative treatment for debilitating and often deadly cases of recurrent C diff infection has been given a Breakthrough Therapy Designation by the FDA. Developed by US biotech firm Rebiotix ...

Second, a Canadian randomised placebo-controlled trial in 21 individuals comparing a single dose of allogenic with autologous FMT via nasoduodenal tube found an improvement in intestinal barrier ...